Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL272524 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2B | |
| SCHEMBL12003052 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2B | |
| SCHEMBL4329020 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2B | |
| SCHEMBL278643 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2B | |
| SCHEMBL13437816 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2B | |
| SCHEMBL7804687 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2B | |
| SCHEMBL13403865 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2B | |
| SCHEMBL12003035 | 0.99 | ADORA2A (0.98) | ADORA2AADORA2B | |
| SCHEMBL13403872 | 0.99 | ADORA2A (0.98) | ADORA2AADORA2B | |
| SCHEMBL272221 | 0.99 | ADORA2A (0.98) | ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090317331-A1 | Method of Identifying Partial Agonists of the A2A Receptor | CV THERAPEUTICS, INC. | 2009-12-24 | — | — | US | claimed |
| US-7582617-B2 | Myocardial perfusion imaging method | CV THERAPEUTICS, INC. (US) | 2009-09-01 | — | — | US | claimed |
| EP-2068850-A1 | USE OF A2A ADENOSINE RECEPTOR AGONISTS IN THE TREATMENT OF ISCHEMIA | CV THERAPEUTICS, INC. (US) | 2009-06-17 | — | — | EP | claimed |
| WO-2008063712-A1 | USE OF A2A ADENOSINE RECEPTOR AGONISTS IN THE TREATMENT OF ISCHEMIA | CV THERAPEUTICS, INC. (US) | 2008-05-29 | — | — | WO | claimed |
| EP-2068850-A1 | USE OF A2A ADENOSINE RECEPTOR AGONISTS IN THE TREATMENT OF ISCHEMIA | CV THERAPEUTICS, INC. (US) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008063712-A1 | USE OF A2A ADENOSINE RECEPTOR AGONISTS IN THE TREATMENT OF ISCHEMIA | CV THERAPEUTICS, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090317331-A1 | Method of Identifying Partial Agonists of the A2A Receptor | ADORA2A, TBXA2R, ADORA3 | ADORA2A 1/4885ADORA2B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.